Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
EP05.01 - Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
-
+
EP05.01-001 - Hispanic Patients with Unresectable Stage III NSCLC under PACIFIC Protocol: Evidence of Interior Outcomes and Health Inequity
Presenter: Andres F Cardona- Abstract
Loading... -
+
EP05.01-002 - Real World Treatment Patterns and Outcomes among Unresectable Stage III Non-Small Cell Lung Cancer Patients Initiating Chemoradiotherapy
Presenter: ASHWINI ARUNACHALAM- Abstract
Loading... -
+
EP05.01-003 - First Real-World Data on Unresectable Stage III NSCLC Patients Treated with Durvalumab after Chemoradiotherapy in Asia Area
Presenter: ChihHsi Kuo- Abstract
Loading... -
+
EP05.01-004 - Induction Chemoimmunotherapy before Definitive Chemoradiotherapy for Large-Volume Unresectable Locally Advanced NSCLC
Presenter: Yu Wang- Abstract
Loading... -
+
EP05.01-005 - Impact of Antibiotic Use Before Definitive Concurrent Chemoradiation in Patients With Locally Advanced Non Small Cell Lung Cancer
Presenter: Youling Gong- Abstract
Loading... -
+
EP05.01-006 - Population Kinetic Assessment of Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Presenter: DAVID J. STEWART- Abstract
Loading... -
+
EP05.01-007 - CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC)
Presenter: Gerard M Walls- Abstract
Loading... -
+
EP05.01-008 - The Scottish Inflammatory Prognostic Score predicts survival in non-small cell lung cancer treated with chemoradiotherapy
Presenter: Grace Ball- Abstract
Loading... -
+
EP05.01-009 - A Clinical Outcome Comparison of IMRT and VMAT in Stage II and III NSCLC Irradiated with Radical Intent
Presenter: Jose Belderbos- Abstract
Loading... -
+
EP05.01-010 - External Validation of Two Prediction Models for Severe Radiation-induced Lymphopenia during Concurrent Chemoradiotherapy for Lung Cancer
Presenter: Jose Belderbos- Abstract
Loading... -
+
EP05.01-011 - Real World Outcomes of Durvalumab after Chemoradiotherapy in unresectable advanced Non-Small Cell Lung Cancer: The Mayo Clinic Experience.
Presenter: Joel Rivera Concepcion- Abstract
Loading... -
+
EP05.01-012 - Avoiding Cardiac Toxicity in Lung Cancer Radiotherapy (ACcoLade) Trial - Initial Results
Presenter: Kathryn Banfill- Abstract
Loading... -
+
EP05.01-013 - Increased C-reactive Protein after Chemoradiotherapy and Immunotherapy in Locally Advanced Non-small Lung Cancer Indicates Worse Survival
Presenter: Karmen Stanic- Abstract
Loading... -
+
EP05.01-014 - Circulating Tumor DNA to Identify Genomic Biomarkers of Radiation Sensitivity in Locally Advanced Non-Small Cell Lung Cancer
Presenter: Emily Lebow- Abstract
Loading... -
+
EP05.01-015 - Validate Radiomics Features and XGBoost Model in Radiation Pneumonitis (RP) Prediction in Patients with Primary Lung Cancer: A MultiCenter Study
Presenter: Jiali Liu- Abstract
Loading... -
+
EP05.01-016 - Radiation Recall Pneumonitis (RRP) Induced by Immune Checkpoint Inhibitors (ICIs) after Thoracic Radiotherapy for Lung Cancer
Presenter: Xiaotong Lu- Abstract
Loading... -
+
EP05.01-017 - Exploring the Benefits of Adaptive Radiotherapy in NSCLC-patients
Presenter: Marie Tvilum- Abstract
Loading... -
+
EP05.01-018 - Chemoradiotherapy Followed by Durvalumab in Unresectable Locally Advanced NSCLC- A Single Institution Experience in Croatia
Presenter: Marko Jakopovic- Abstract
Loading... -
+
EP05.01-019 - 4D CT Ventilation Image-Guided Lung Functional Avoidance Radiotherapy: A Single-Arm Prospective Pilot Clinical Trial
Presenter: Megan Eileen Daly- Abstract
Loading... -
+
EP05.01-020 - Unanticipated Radiation Re-planning for Stage III Non-small Cell Lung Cancer
Presenter: MELINDA MUSHONGA- Abstract
Loading... -
+
EP05.01-021 - Radiation Dose to Cardiac Substructures and the Incidence of Cardiac Events in Patients with Stage III NSCLC Receiving CCRT
Presenter: Meng Xu Welliver- Abstract
Loading... -
+
EP05.01-022 - Evaluation of the Management of Stage III NSCLC at Mohamed IV Center for Cancer Treatment Casablanca
Presenter: Maryam ZAOUIT- Abstract
Loading... -
+
EP05.01-023 - Feasibility of Functional Lung Avoidance using Ga-68 4D Ventilation Perfusion PET/CT: The HI-FIVE Trial
Presenter: Nicholas Wentworth Bucknell- Abstract
Loading... -
+
EP05.01-024 - Real-life Management of Stage III NSCLC Patients in Italy: The BE-PACIFIC Observational Study
Presenter: Paolo Bironzo- Abstract
Loading... -
+
EP05.01-025 - Planned Interim Analysis of a Phase II Trial of Concurrent Durvalumab and Radiation Therapy for Locally Advanced Lung Cancer
Presenter: Andreas Rimner- Abstract
Loading... -
+
EP05.01-026 - Carboplatin Dose Calculations for Patients with Lung Cancer: Significant Dose Differences Found Depending on Dosing Equation
Presenter: Seçkin Akgül- Abstract
Loading... -
+
EP05.01-027 - Uncertain Resection of pN2 NSCLC Patients-survival Analysis of Postoperative Radiotherapy and Driver Gene Mutations
Presenter: Qianyue Deng- Abstract
Loading... -
+
EP05.01-028 - Thoracic Radiotherapy of Baseline Severe Pulmonary Dysfunction NSCLC Patients and Predictive Analysis for Acute Radiation Pneumonitis
Presenter: Qianyue Deng- Abstract
Loading... -
+
EP05.01-029 - Association between DNA Repair Gene Pathway SNPs and Tumour Response in NSCLC Patients Receiving Radiotherapy: A Meta-Analysis
Presenter: Timothy Shun Man Chu- Abstract
Loading... -
+
EP05.01-030 - CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany - AIO-TRK-0315
Presenter: Wilfried Ernst Erich Eberhardt- Abstract
Loading... -
+
EP05.01-031 - Lysimachia Capillipes Capilliposide C Enhances the Radiosensitivity of Lung Cancer by Promoting ERRFI1 via Inhibiting Phosphorylation of STAT3
Presenter: Kan Wu- Abstract
Loading... -
+
EP05.01-032 - The Incidence of Brain Metastasis and Radiation Pneumonitis With Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
Presenter: Yeon Sil Kim- Abstract
Loading... -
+
EP05.01-033 - Stimulation CT-Based Radiomics Predict Radiation Pneumonitis after Chemoradiotherapy in Locally Advanced NSCLC
Presenter: Haihua Yang- Abstract
Loading... -
+
EP05.01-036 - Role of Nanoparticle Polymeric Micellar Paclitaxel in Reducing Toxicity and Enhancing Efficacy in Non-small Cell Lung Cancer
Presenter: Baohui Han- Abstract
Loading...
-
+
EP05.02 - Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
-
+
EP05.02-001 - Early Treatment Failure Of Consolidation Durvalumab for Unresectable Stage III NSCLC: A Real-World Canadian Cohort
Presenter: Amanda Gibson- Abstract
Loading... -
+
EP05.02-002 - Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?
Presenter: Blanca Távara- Abstract
Loading... -
+
EP05.02-003 - Durvalumab after Chemoradiotherapy (CRT) in Unresectable Stage III NSCLC. Comparative Study of Two Cohorts in the Real-World Setting.
Presenter: Blanca Távara- Abstract
Loading... -
+
EP05.02-004 - Could Fifty Percent Tumor Viability Be a Good Prognostic Factor?
Presenter: Ezgi Cesur- Abstract
Loading... -
+
EP05.02-005 - Is Immunotherapy Safer Than Radiotherapy in Combination With Chemotherapy in Neoadjuvant Therapy?
Presenter: Ezgi Cesur- Abstract
Loading... -
+
EP05.02-006 - Neoadjuvant DS-8201 for Stage III Non-small Cell Lung Cancer with HER2 20ins
Presenter: Huizhao Hong- Abstract
Loading... -
+
EP05.02-007 - Impact Of Fibrinogen Levels and mGPS on Survival of Stage III/N2 NSCLC Patients Treated with Neoadjuvant Therapy and Radical Surgery
Presenter: Katharina Sinn- Abstract
Loading... -
+
EP05.02-008 - Phase II Trial of Neoadjuvant Icotinib Plus Chemotherapy for Stage II-IIIB EGFR-mutant Non-small-Cell Lung Cancer
Presenter: Fang-Liang Lu- Abstract
Loading... -
+
EP05.02-009 - Aumolertinib Versus Erlotinib/Chemotherapy for Neoadjuvant Treatment of Stage IIIA EGFR-mutant NSCLC (ANSWER)
Presenter: Wenhua Liang- Abstract
Loading... -
+
EP05.02-010 - Robotic-Assisted Thoracic Surgery Following Neoadjuvant Chemoimmunotherapy in Patients with Stage III Non-small Cell Lung Cancer
Presenter: Min Li- Abstract
Loading... -
+
EP05.02-011 - Phase II Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer
Presenter: Yao-Bin Lin- Abstract
Loading... -
+
EP05.02-012 - Chemoradiotherapy versus Chemotherapy in Neoadjuvant Settings for Stage III-N2M0 Non-Small Cell Lung Cancer (NSCLC) Patients
Presenter: Marah Akhdar- Abstract
Loading... -
+
EP05.02-013 - Immune-Related Adverse Effects and Durvalumab Treatment Patterns in VHA Patients with Unresectable Stage III NSCLC
Presenter: Amanda M Moore- Abstract
Loading... -
+
EP05.02-014 - Neoadjuvant Toripalimab Combination in Patients with Stage IIB-IIIB NSCLC: A Single-Arm, Phase 2 Trial (Renaissance Study)
Presenter: Shi Yan- Abstract
Loading... -
+
EP05.02-015 - Neoadjuvant Prehabilitation Therapy for Locally Advanced Non-small-Cell Lung Cancer: Optimizing Outcomes throughout the Trajectory of Care.
Presenter: Severin Schmid- Abstract
Loading... -
+
EP05.02-016 - Aumolertinib after Adjuvant Chemotherapy/Radiotherapy in Stage pIIIA-N2 Non-Small-Cell Lung Cancer with EGFR Mutation
Presenter: Yu Zhang- Abstract
Loading... -
+
EP05.02-017 - Prognostic Factors Following Induction Therapy for N2 Lung Cancer
Presenter: Takashi Inoue- Abstract
Loading... -
+
EP05.02-019 - Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Surgical Outcomes in a Regionalized Pulmonary Oncology Network
Presenter: Yohann Pilon- Abstract
Loading... -
+
EP05.02-020 - IL-9Stimulates Anti-tumor Immune Response and Facilitates Checkpoint Blockade in Lung Cancer
Presenter: Yuqian Feng- Abstract
Loading... -
+
EP05.02-021 - An Updated Analysis of Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable NSCLC
Presenter: Yongchang Zhang- Abstract
Loading... -
+
EP05.02-022 - Thoracic Radiotherapy May Increase the Risk of Treatment-induced Pneumonitis after Immune Checkpoint Inhibitors: A Meta-Analysis
Presenter: Feng-Ming Spring Kong- Abstract
Loading...
-
+
EP05.03 - Locally Advanced Non-small Cell Lung Cancer - Surgery
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Locally Advanced Non-small Cell Lung Cancer - Surgery
-
+
EP05.03-001 - Impact of Neoadjuvant Chemo/radiotherapy Followed by Surgical Resection on T4N0-1 Non-Small Cell Lung Cancer
Presenter: Akif Turna- Abstract
Loading... -
+
EP05.03-002 - Pulmonary Artery Reconstruction for Lung Cancer With N1 Vessel Infiltration: Is It Justified?
Presenter: Camilla Vanni- Abstract
Loading... -
+
EP05.03-003 - Superior Sulcus (Pancoast) Tumors: A 11-Year Single-Centre Experience
Presenter: Catarina Pereira Moita- Abstract
Loading... -
+
EP05.03-004 - Risk Prediction of Multiple-station N2 Metastasis in Patients with Clinical Single-station N2 Non-small Cell Lung Cancer
Presenter: Joon Young Kim- Abstract
Loading... -
+
EP05.03-005 - Clinical Impact of Histologic Type in Patients with Surgically Resected Stage II and III Non-small Cell Lung Cancer
Presenter: Hyeong Ryul Kim- Abstract
Loading... -
+
EP05.03-006 - Real-World Treatment Pathways In Stage III Non-Small Cell Lung Cancer in Portugal (PICTuRE): An Interim Analysis Of Surgical Patients
Presenter: Maria Encarnação Teixeira- Abstract
Loading... -
+
EP05.03-007 - Comparison of Surgical Methods in Patients Receiving Neoadjuvant Treatment; Thoracoscopy vs. thoracotomy
Presenter: Ezgi Cesur- Abstract
Loading... -
+
EP05.03-008 - Surgery after First-Line Alectinib for (Locally) Advanced ALK-rearranged NSCLC: Pathological Response and Peri-Operative Results
Presenter: Filippo Lococo- Abstract
Loading... -
+
EP05.03-009 - Prognostic Impact of Tumor Volume Doubling Time for Resected Squamous Cell Carcinoma of the Lung
Presenter: Kenta Nakahashi- Abstract
Loading... -
+
EP05.03-010 - Extended Resection of Non-small Cell Lung Cancer with Superior Vena Cava Involvement: A Systematic Review and Meta-analysis
Presenter: Shadi Hamouri- Abstract
Loading... -
+
EP05.03-011 - Bilateral Orthotopic Lung Transplantation for a Patient with Advanced Invasive Mucinous Adenocarcinoma
Presenter: Young Kwang Chae- Abstract
Loading... -
+
EP05.03-012 - Deep Learning-based Classifier to Predict Intensified Locoregional Approach Need in Stage III Non-Small Cell Lung Cancer
Presenter: Chenchen Zhang- Abstract
Loading...
-
+
EP06.01 - Management of Lung Cancer in the Era of COVID-19
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Management of Lung Cancer in the Era of COVID-19
-
+
EP06.01-001 - The Longitudinal Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Centre: A Retrospective Chart Review
Presenter: Angelo Rizzolo- Abstract
Loading... -
+
EP06.01-002 - Cancer Care in a Time of COVID: Lung Cancer Patient’s Experience of Telehealth and Connectedness.
Presenter: Anne Fraser- Abstract
Loading... -
+
EP06.01-003 - Impact of COVID-19 on Lung Cancer Patients; The Patients’ Perspective
Presenter: Desiree Hao- Abstract
Loading... -
+
EP06.01-004 - Lung Cancer Resection During the Covid-19 Pandemic: A Single Centre Study
Presenter: Tunde Nureini Oyebanji- Abstract
Loading... -
+
EP06.01-005 - COVID-19 and Post-COVID Outcomes in Lung Cancer Patients: Experience from an Indian Cancer Center
Presenter: Debapriya Mondal- Abstract
Loading... -
+
EP06.01-006 - Multidisciplinary Team during the COVID-19 Pandemic: The BE-PACIFIC Italian Observational Study Analysis.
Presenter: Enrica Capelletto- Abstract
Loading... -
+
EP06.01-007 - Fate of Pneumonectomy Patients During Covid-19 Pandemic
Presenter: Gökberk Güler- Abstract
Loading... -
+
EP06.01-008 - COVID-Protected Pathways for Image Guided Lunc Cancer Intervention During the COVID-19 Pandemic: A Cohort Study
Presenter: Alexander Sheeka- Abstract
Loading... -
+
EP06.01-009 - Maintaining Thoracic Services During COVID-19 - A Single Centre Experience
Presenter: Hasanali David Walji- Abstract
Loading... -
+
EP06.01-010 - Clinical Outcomes after Hypo Fractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer During The Covid-19 Pandemic In Morocco
Presenter: Meriem cherkaoui- Abstract
Loading... -
+
EP06.01-011 - COVID-19 Impact in Thoracic Surgery: a Comparison Between Public and Private Care in a Single-Center Facility
Presenter: Maria Teresa Ruiz Tsukazan- Abstract
Loading... -
+
EP06.01-012 - Impact of COVID-19 on the Stage of Lung Cancer Diagnosis at the Mohamed VI Center for Cancer Treatment in Morocco
Presenter: Souleymane PANANDTIGRI- Abstract
Loading... -
+
EP06.01-013 - Differences of Oncology Treatment for Lung Cancer Patients in Pandemic COVID-19 Yearꓽ Our Clinical Experience
Presenter: simonida crvenkova- Abstract
Loading... -
+
EP06.01-014 - Lung Resections After COVID: Short-term Outcomes
Presenter: Srinivas Kodaganur Gopinath- Abstract
Loading... -
+
EP06.01-015 - Will Virtual Care Stand the Test of Time; One Site’s Perspective on the Continuity of Virtual Care Post-Pandemic
Presenter: Suheon Lee- Abstract
Loading... -
+
EP06.01-016 - Nationwide Activity of Lung Cancer Surgery Before and During the COVID-19 Pandemic
Presenter: Tanel Laisaar- Abstract
Loading... -
+
EP06.01-017 - Clinical Impact of SARS-CoV2 Pandemic in the Diagnosis of Early-Stage Thoracic Tumours
Presenter: Yago Garitaonaindía Díaz- Abstract
Loading...
-
+
EP07.01 - Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical
-
+
EP07.01-001 - Molecular Profiling Predicts Outcomes in Patients With Resected Malignant Pleural Mesothelioma
Presenter: Christian Diego Rolfo- Abstract
Loading... -
+
EP07.01-002 - Surgery in Stage I-III Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER)- Medicare Analysis 1995-2015
Presenter: Qian Wang- Abstract
Loading... -
+
EP07.01-003 - Metadata-Oriented Data Engineering Approach for Integration of Medical Data: A Pilot Study
Presenter: Yusuf Kahya- Abstract
Loading... -
+
EP07.01-004 - Long Survivor Epithelioid Pleural Mesotheliomas Are Characterized by Tertiary Lymphoid Structures: An Update to the MATCH Study
Presenter: Federica Grosso- Abstract
Loading... -
+
EP07.01-005 - Second Primary Cancers in a Population-Based Mesothelioma Registry
Presenter: Giovanni Luca Ceresoli- Abstract
Loading... -
+
EP07.01-006 - Clinicopathologic Determinants of Survival in Thoracic NUT Carcinoma (TNUT): Analysis of a Pooled Database
Presenter: Philip A Haddad- Abstract
Loading... -
+
EP07.01-007 - Is Extended Resection for Tracheo Bronchial Adenoid Cystic Carcinoma Warranted ?
Presenter: Jérôme Estephan- Abstract
Loading... -
+
EP07.01-008 - Perturbation of Warburg Effect by Dichloroacetate and Niclosamide in Malignant Pleural Mesothelioma in Vitro and in Vivo
Presenter: James C HO- Abstract
Loading... -
+
EP07.01-009 - Solitary Fibrous Tumors of the Pleura, Clinical and Surgical Dilemma. Single-Center Experience
Presenter: Krzysztof Kurowski- Abstract
Loading... -
+
EP07.01-010 - Results of Multimodal Treatment in Patients with Malignant Pleural Mesothelioma Undergoing Pleurectomy/Decortication
Presenter: Kubra Alphan Kavak- Abstract
Loading... -
+
EP07.01-011 - Integrating PD-L1 Expression to the CALGB Prognostic Scoring System in Malignant Pleural Mesothelioma
Presenter: Luis Antonio Cabrera- Abstract
Loading... -
+
EP07.01-012 - Ipilimumab and Nivolumab in Pretreated Patients with Malignant Pleural Mesothelioma
Presenter: Marko Jakopovic- Abstract
Loading... -
+
EP07.01-013 - Physical Function, Symptom Burden, and Quality of Life in Patients with Malignant Pleural Mesothelioma
Presenter: Meng Wu- Abstract
Loading... -
+
EP07.01-014 - Mesothelioma-Associated Fibroblasts Enhance Mesothelioma Aggressiveness and Modulate Drug Response
Presenter: Michael Grusch- Abstract
Loading... -
+
EP07.01-015 - Multimodality Imaging for Characterization, Classification, and Staging of Malignant Pleural Mesothelioma, Focusing on MR Imaging
Presenter: Mi young Kim- Abstract
Loading... -
+
EP07.01-016 - Role of Neoadjuvant Chemotherapy in Thymic Tumors
Presenter: riad abdeljalil- Abstract
Loading... -
+
EP07.01-017 - Malignant Fibrous Solitary Tumour of the Pleura Is Not All the Same: Evaluation of Risk Stratification Models in a Large Single Centre Series
Presenter: Sara Ricciardi- Abstract
Loading... -
+
EP07.01-018 - Phase III Randomized Trial on Surgery, Chemo and Pleural Radiation (IMPRINT) for Resectable Pleural Mesothelioma (NRG LU-006)
Presenter: Andreas Rimner- Abstract
Loading... -
+
EP07.01-019 - Multiinstitutional Patterns of Use and Compliance with Tumor Treating Fields for Patients with Unresectable Malignant Pleural Mesothelioma
Presenter: Rupesh Kotecha- Abstract
Loading... -
+
EP07.01-020 - Pulmonary MALT Lymphoma: Detailed CT Findings
Presenter: Kyongmin Sarah Beck- Abstract
Loading... -
+
EP07.01-021 - Clinical and Biochemical Profiling of Pleural Mesothelioma Patients Treated With Immunotherapy
Presenter: Sara Manglaviti- Abstract
Loading... -
+
EP07.01-022 - Analysis of Second Surgery for Recurrence in Malignant Pleural Mesothelioma (MPM) Patients (P)
Presenter: Susana Cedres- Abstract
Loading... -
+
EP07.01-023 - Family History of Cancer in a Series of Malignant Pleural Mesothelioma (MPM) Patients (P)
Presenter: Susana Cedres- Abstract
Loading... -
+
EP07.01-024 - Preclinical Investigation of Immune Checkpoint Blockade and Anti-Angiogenic Therapy in Malignant Pleural Mesothelioma
Presenter: Sophie Rovers- Abstract
Loading... -
+
EP07.01-025 - Survival Advantage of Pulmonary Metastasectomy in Advanced Melanoma Patients: A Population-Based Study
Presenter: Sebawe Syaj- Abstract
Loading... -
+
EP07.01-026 - Primary Pulmonary Ewing´S Sarcoma: Post Hoc Analysis From Two International Multicenter Prospective Randomized Trials
Presenter: Theresa Stork- Abstract
Loading...
-
+
EP07.02 - Mesothelioma, Thymoma, and Other Thoracic Malignancies - Preclinical
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies - Preclinical
-
+
EP07.02-001 - Evaluation of FGF18 as a Contributing Factor in Malignant Pleural Mesothelioma Growth and Its Role as a Potential Biomarker
Presenter: Berta Mosleh- Abstract
Loading... -
+
EP07.02-002 - Investigating the Role of MicroRNAs in Cell Growth and Cisplatin-Sensitivity of Malignant Pleural Mesothelioma
Presenter: Michaela B Kirschner- Abstract
Loading... -
+
EP07.02-003 - Characterization of the Extracellular Vesicle-Derived Transcriptome in Malignant Pleural Mesothelioma
Presenter: Michaela B Kirschner- Abstract
Loading... -
+
EP07.02-004 - Endogenous Retrovirus Expression and Type I Interferon Signaling in Human Mesothelioma
Presenter: Suna Sun- Abstract
Loading...
-
+
EP07.03 - Mesothelioma, Thymoma, and Other Thoracic Malignancies - Thymoma
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies - Thymoma
-
+
EP07.03-001 - Comparison of Treatment Outcomes in Neoadjuvant Chemotherapy and Chemo-radiotherapy for Thymoma and Thymic Carcinoma
Presenter: Hyeon Seok Choi- Abstract
Loading... -
+
EP07.03-002 - Combined Classifications for Thymoma and Thymic Carcinoma From a 10 years CHUM University Hospital Real-world Experience
Presenter: Camille Gauvin- Abstract
Loading... -
+
EP07.03-003 - First Line Combination of Toripalimab and Chemotherapy in Advanced Thymic Carcinoma: A Single-Center, Prospective, Single-Arm, Phase II Trial
Presenter: Xingsheng Hu- Abstract
Loading... -
+
EP07.03-004 - Efficacy of Thoracic Radiotherapy for Local Progression in Advanced Thymic Carcinoma
Presenter: Mao Uematsu- Abstract
Loading... -
+
EP07.03-005 - MesoGraph: Graph Neural Networks for Weakly Supervised Cellular Profiling in the Subtyping of Malignant Mesothelioma Images
Presenter: Mark Eastwood- Abstract
Loading... -
+
EP07.03-006 - Feasibility of TTFields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Real-World Data
Presenter: Rupesh Kotecha- Abstract
Loading... -
+
EP07.03-007 - Clinicopathological Analyses for Predicting Recurrence After Complete Resection of Thymoma
Presenter: Takahiro Suzuki- Abstract
Loading...
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
EP08.01-001 - Update Analysis of Sintilimab With Two Cycles Chemotherapy for Untreated Advanced Squamous Non-small-Cell Lung Cancer
Presenter: Huijuan Wang- Abstract
Loading... -
+
EP08.01-002 - Real-World Survival Outcomes of Patients with High PD-L1 Advanced NSCLC Who Received Chemo-Immunotherapy vs Immunotherapy
Presenter: Junipearl Cheng- Abstract
Loading... -
+
EP08.01-003 - Efficacy of Immune Checkpoint Inhibitors in Pulmonary Sarcomatoid Carcinoma, A Multicenter Retrospective Study
Presenter: Zhimin Zeng- Abstract
Loading... -
+
EP08.01-004 - Pattern of Subsequent Treatment and Outcomes in Relapsed PD-L1 high NSCLC Pre-treated with Pembrolizumab
Presenter: Anifat Elegbede- Abstract
Loading... -
+
EP08.01-005 - A Multicenter Prospective Observational Study of Atezolizumab in Unresectable Advanced or Metastatic NSCLC in Japan: J-TAIL
Presenter: Akito Hata- Abstract
Loading... -
+
EP08.01-006 - Using Real World data to build effective predictive machine learining models for NSCLC patients treated with immune-based therapy
Presenter: Alessandro De Toma- Abstract
Loading... -
+
EP08.01-007 - Real-World Outcomes of Patients with Advanced Lung Adenocarcinoma Treated with First-Line Chemo-Immunotherapy in Italy
Presenter: Alessandro Leonetti- Abstract
Loading... -
+
EP08.01-008 - Immune Checkpoint Inhibitors in Oncogenic Driven Non-small Cell Lung Cancer
Presenter: Ana Fonseca- Abstract
Loading... -
+
EP08.01-009 - TRBV Haplotype Profile Was Related to Immune-Induced Adverse Events in Chinese Patients With Advanced NSCLC
Presenter: Xiaomin Niu- Abstract
Loading... -
+
EP08.01-010 - Troponin Elevation and the Risk of Myocarditis among NSCLC Patients Treated with Immune Checkpoint Inhibitors
Presenter: Barliz Waissengrin- Abstract
Loading... -
+
EP08.01-011 - Diabetes Mellitus (DM) is Associated with Poor Outcome in Pembrolizumab-treated Non-Small Cell Lung Cancer (NSCLC) Patients
Presenter: Barliz Waissengrin- Abstract
Loading... -
+
EP08.01-012 - First-line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer with 0-49% PD-L1: A Real-world Experience
Presenter: Beatrice Benetti- Abstract
Loading... -
+
EP08.01-013 - Ramucirumab plus Atezolizumab in Patients with Stage IV NSCLC Previously Treated with Immune Checkpoint Blockade
Presenter: Brett Howard Herzog- Abstract
Loading... -
+
EP08.01-014 - Tislelizumab versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer: Final Analysis of RATIONALE-303
Presenter: Caicun Zhou- Abstract
Loading... -
+
EP08.01-015 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Anti-oxMIF Antibody ON203 in Malignant Solid Tumors
Presenter: Christine Landlinger-Schubert- Abstract
Loading... -
+
EP08.01-016 - A Review Of Real-World Treatment Outcomes Of mNSCLC Patients Following Progression On Or After Platinum-Based Chemotherapy
Presenter: Cloe Ying Chee Koh- Abstract
Loading... -
+
EP08.01-017 - Evaluation of Blood Tumor Mutation Burden for Efficacy of Second- Line Atezolizumab Treatment in Non-small Cell Lung Cancer
Presenter: Cheol-Kyu Park- Abstract
Loading... -
+
EP08.01-018 - Patterns of Failure in Metastatic NSCLC Treated with First Line Pembrolizumab and Impact of Local Therapy in Patients with Oligoprogression
Presenter: Cole Friedes- Abstract
Loading... -
+
EP08.01-019 - Modifiable biomarkers of response to immune checkpoint inhibitor treatment in non-small cell lung cancer
Presenter: Daniel Spakowicz- Abstract
Loading... -
+
EP08.01-020 - Phase 2 Platform Trial of Anti-TIGIT GSK’859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)
Presenter: David Spigel- Abstract
Loading... -
+
EP08.01-021 - Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy
Presenter: SHOURYADEEP SRIVASTAVA- Abstract
Loading... -
+
EP08.01-022 - Treatment Outcomes of Second-Line Immune Modulators in Steroid Refractory/Resistant Immune Related Adverse Events
Presenter: Yasar Ahmed- Abstract
Loading... -
+
EP08.01-023 - Factors Associated with Survival and Refusal of Physician Recommended Immunotherapy in Metastatic Non Small Cell Lung Cancer
Presenter: Iktej Singh Jabbal- Abstract
Loading... -
+
EP08.01-024 - Multicenter Real Life Clinical Outcomes of PDL-1 Tested Patients with Non Small Cell Lung Cancer (NSCLC) in Turkey
Presenter: Ozan Yazici- Abstract
Loading... -
+
EP08.01-025 - PD-L1 Tumor Tissue Expression and Its Relation with Clinico-pathological Profile in Advanced NSCLC
Presenter: Sindhu Kilaru- Abstract
Loading... -
+
EP08.01-026 - Influence of Brain Metastases on Survival of KRASG12C Mutated Stage IV Immune Checkpoint Inhibitor Treated Non-Small Cell Lung Cancer Patients
Presenter: Esther M Swart- Abstract
Loading... -
+
EP08.01-027 - Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON
Presenter: Edward B. Garon- Abstract
Loading... -
+
EP08.01-028 - Overestimation with Cox HR - Cox-TEL-Adjusted Associations of PD-L1 Expression with Immune Checkpoint Inhibitor Survival Benefit in Lung Cancer
Presenter: Emily Pei-Ying Lin- Abstract
Loading... -
+
EP08.01-029 - NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases
Presenter: Ernest Nadal- Abstract
Loading... -
+
EP08.01-030 - Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial
Presenter: Federico Cappuzzo- Abstract
Loading... -
+
EP08.01-031 - Blood Gene Expression Changes in Metastatic Lung Cancer under second-line Immunotherapy according to Clinical Response
Presenter: Fabienne Dorothea Lusky- Abstract
Loading... -
+
EP08.01-032 - Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study
Presenter: Yun Fan- Abstract
Loading... -
+
EP08.01-033 - ML40471: Preliminary Analysis of Atezolizumab in Previously Treated Patients With Locally Advanced or Metastatic NSCLC
Presenter: Yun Fan- Abstract
Loading... -
+
EP08.01-034 - Association of Sarcopenia with Survival in Advanced NSCLC Patients Receiving Concurrent Immunotherapy and Chemotherapy
Presenter: Fabian Johannes Bolte- Abstract
Loading... -
+
EP08.01-035 - Personalized ctDNA Detection to Monitor Outcome and Predict Immunotherapy Benefit in Locally Advanced and Metastatic NSCLC
Presenter: Guanghui Gao- Abstract
Loading... -
+
EP08.01-036 - Low-dose EGFR-TKIs Directly Induce Maturation and Functional Activity of Human Dendritic Cells in an EGFR-independent manner
Presenter: Hiroyuki Inoue- Abstract
Loading... -
+
EP08.01-037 - Association of Baseline NLR and BMI with Clinical Outcomes in NSCLC Patients Treated with Immunotherapy Alone Versus Chemo-Immunotherapy
Presenter: Hita Moudgalya- Abstract
Loading... -
+
EP08.01-038 - Clinical Predictors of Treatment Efficacy in Patients with Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors
Presenter: Fang Hu- Abstract
Loading... -
+
EP08.01-039 - Impact of Pulmonary Function Indexes on Immunotherapy Efficacy in Lung Adenocarcinoma Patients and the Potential Prognostic Factors
Presenter: Fang Hu- Abstract
Loading... -
+
EP08.01-040 - Peripheral Blood Cells as Predictors for Efficacy of Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer
Presenter: Jacobo Rogado- Abstract
Loading... -
+
EP08.01-041 - Impact of Gender on Response to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer
Presenter: Jae Cheol Lee- Abstract
Loading... -
+
EP08.01-042 - NEPTUNE China Cohort: First-Line Durvalumab + Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC
Presenter: Ying Cheng- Abstract
Loading... -
+
EP08.01-043 - Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced Non-small Cell Lung Cancer (NSCLC)
Presenter: Joao Alessi- Abstract
Loading... -
+
EP08.01-044 - A Phase 2 Multi-Cohort Study of Tiragolumab, Atezolizumab and Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Cancer
Presenter: Joshua Reuss- Abstract
Loading... -
+
EP08.01-045 - The Impact of Current Smoking Status at Initiation of Immune Checkpoint Inhibitor Therapy on Tumor Mutation Burden and Survival
Presenter: Julie T. Wu- Abstract
Loading... -
+
EP08.01-046 - Examination of Long-Term Administration of Pembrolizumab in Patients with Non-small Cell Lung Cancer at Our Institution
Presenter: Kazuhito Nii- Abstract
Loading... -
+
EP08.01-047 - Chemo-immunotherapy is Associated With Better Survival Than Chemotherapy Alone In Stage IV Non-small Cell Lung Cancer
Presenter: Krishna Hitendra Patel- Abstract
Loading... -
+
EP08.01-048 - Spanish Immunotherapy Registry of Cardiovascular Toxicity (SIR-CVT): Preliminary Analysis of the Lung Cancer Cohort
Presenter: Laura Gutiérrez Sainz- Abstract
Loading... -
+
EP08.01-049 - Unscheduled Hospitalizations in Patients With Thoracic Tumors in the Era of Immunotherapy
Presenter: Laura Gutiérrez Sainz- Abstract
Loading... -
+
EP08.01-050 - Survival Outcome of Metastatic Pulmonary Sarcomatoid Carcinoma Treated with Immunotherapy: An Analysis of National Cancer Database (NCDB)
Presenter: Lei Deng- Abstract
Loading... -
+
EP08.01-051 - Clinical Characterization and Outcomes of Non Small Cell Lung Cancer with HER2 Alterations in the Era of Immunotherapy
Presenter: Shenduo Li- Abstract
Loading... -
+
EP08.01-052 - Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study
Presenter: Xuxinyi Ling- Abstract
Loading... -
+
EP08.01-053 - PD-1 Inhibitors Plus Chemotherapy in Patients with Brain Metastasis and EGFR/ALK-positive Non-small Cell Lung Cancer after EGFR/ALK-TKIs
Presenter: Yutao Liu- Abstract
Loading... -
+
EP08.01-054 - ICIs combined with Single-agent Chemotherapy in Two or More Lines Treatment for Advanced Non-Small Cell Lung Cancer
Presenter: Yutao Liu- Abstract
Loading... -
+
EP08.01-055 - Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer
Presenter: Wenbin Li- Abstract
Loading... -
+
EP08.01-056 - Pemetrexed-Based Chemotherapy Plus ICIs or Bevacizumab as First-Line Strategy for Patients with Lung Adenocarcinoma in Real-World Setting
Presenter: Xin Li- Abstract
Loading... -
+
EP08.01-057 - Pembrolizumab Maintenance in Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sNSCLC) - AIO-TRK-0115/PRIMUS
Presenter: Martin Reck- Abstract
Loading... -
+
EP08.01-058 - Access to Immunotherapy in Control Arms of Pivotal First Line Immunotherapy Trials in Metastatic Non-Small Cell Lung Cancer
Presenter: Maham Bakhtyar- Abstract
Loading... -
+
EP08.01-059 - Safety, Tolerability and Clinical Activity of Selinexor in Combination with Pembrolizumab in Metastatic Non-small Cell Lung Cancer
Presenter: Mehmet Altan- Abstract
Loading... -
+
EP08.01-060 - Long term Survival Outcomes in NSCLC Patients with Targeted Therapy and Immunotherapy: An IASLC Analysis of ASCO CancerLinQ Discovery Data
Presenter: Madhusmita Behera- Abstract
Loading... -
+
EP08.01-061 - A Pilot Study of Avelumab and SABR in Non-Responding and Progressing NSCLC Patients Previously Treated with a Checkpoint Inhibitor
Presenter: Megan Eileen Daly- Abstract
Loading... -
+
EP08.01-062 - Body Mass Index, Immune Related Adverse Events, and Survival in Patients with Metastatic Non-small Cell Lung Cancer Treated with Immunotherapy
Presenter: Mingjia Li- Abstract
Loading... -
+
EP08.01-063 - Chemoimmunotherapy versus Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer with a PD-L1 Score of 50-100%
Presenter: Mohsin Shah- Abstract
Loading... -
+
EP08.01-064 - Serum NY-ESO-1 and XAGE1 Antibodies Predict and Monitor Clinical Responses to Immune Checkpoint Therapy for NSCLC
Presenter: Mikio Oka- Abstract
Loading... -
+
EP08.01-065 - Prevalence of Non-driver Mutations and Characterization of Patients with Advanced or Metastatic Non-small Cell Lung Cancer
Presenter: Mariano Provencio- Abstract
Loading... -
+
EP08.01-066 - Assessing Immunotherapy in Real Life: Have We Transferred the Increase in Overall Survival in Stage IV NSCLC from Trials to Clinical Practice?
Presenter: Mariano Provencio- Abstract
Loading... -
+
EP08.01-067 - Rechallenging with PD-1 Inhibitors: Incidence and Management of Immune-Related Adverse Events in Metastatic NSCLC
Presenter: Tuan Hoang- Abstract
Loading... -
+
EP08.01-068 - Going for the Ligand After a Stint With the Receptor: Can Switching Target From PD-1 to PD-L1 (Or Vice-Versa) Be Beneficial?
Presenter: Nida Khan- Abstract
Loading... -
+
EP08.01-069 - A Retrospective Study of Immune Checkpoints Rechallenge/ Retreatment in Metastatic NSCLC Progressing after Previous ICIs
Presenter: Nuria Neisy Mederos Alfonso- Abstract
Loading... -
+
EP08.01-070 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
Presenter: Jun Zhao- Abstract
Loading... -
+
EP08.01-071 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC
Presenter: Jun Zhao- Abstract
Loading... -
+
EP08.01-072 - Clinical Value of Patras Immunotherapy Score (PIOS) Formula in Patients With Advanced NSCLC Treated With Immunotherapy/Chemotherapy
Presenter: Petros Christopoulos- Abstract
Loading... -
+
EP08.01-073 - AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC
Presenter: Rajiv Kumar- Abstract
Loading... -
+
EP08.01-074 - 'Long Responders' Compared to 'Non-Responders' to a First Line Immune Checkpoint Inhibitor in Incurable Non-Small Cell Lung Cancer
Presenter: Rebekah Rittberg- Abstract
Loading... -
+
EP08.01-075 - Combination of Baseline Disease and Smoking Pack-Years Can Guide The 1st-line Treatment Decision in Advanced NSCLC with High PD-L1 Expression
Presenter: Ren Yuan- Abstract
Loading... -
+
EP08.01-076 - KEYNOTE B36: A Pilot Study of First-line Tumor Treating Fields (150 kHz) Plus Pembrolizumab for Advanced or Metastatic Non-small Cell Lung Cancer
Presenter: Rupesh Kotecha- Abstract
Loading... -
+
EP08.01-077 - Predicting Response to Checkpoint Inhibitors Using Complex Molecular Characteristics and Immunoprofiling in Patients With NSCLC
Presenter: Simona Borilova- Abstract
Loading... -
+
EP08.01-078 - Clinical Outcomes in Metastatic Non-small Cell Lung Cancer Harboring BRAF Mutations Treated With Immune Checkpoint Inhibitors
Presenter: Susana Cedres- Abstract
Loading... -
+
EP08.01-080 - Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced NSCLC in Patients aged ≥ 70
Presenter: Bo Shen- Abstract
Loading... -
+
EP08.01-081 - A Phase I Dose-Escalation Study of HBM4003, an anti-CTLA-4 Heavy Chain Only Monoclonal Antibody, in Combination with Pembrolizumab
Presenter: Shun Lu- Abstract
Loading... -
+
EP08.01-082 - Therapeutic Resistance and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients: A Prospective Study
Presenter: Shun Lu- Abstract
Loading... -
+
EP08.01-083 - Real-World PD-(L)1 Inhibitor Treatment Pattern and Outcomes in Advanced Non-Small Cell Lung Cancer in Sweden
Presenter: Simon Ekman- Abstract
Loading... -
+
EP08.01-084 - Non-Invasive Detection of Predictive Biomarkers for PD-1 Inhibitor Treated Non-Small Cell Lung Cancer Patients
Presenter: Simone Stensgaard- Abstract
Loading... -
+
EP08.01-085 - Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer
Presenter: Si-Yang Maggie Liu- Abstract
Loading... -
+
EP08.01-086 - Pooled Mutant KRAS-Targeted Peptide Vaccine with Nivolumab and Ipilimumab in Advanced KRAS Mutated Non-Small Cell Lung Cancer
Presenter: Samuel Rosner- Abstract
Loading... -
+
EP08.01-087 - First-Line Pembrolizumab-Combination Therapy for Advanced Squamous NSCLC: Real-World Outcomes at US Oncology Practices
Presenter: Stephen V. Liu- Abstract
Loading... -
+
EP08.01-088 - Direct Acting Antivirals (DAA) and Immune Checkpoint Inhibitors (ICIs) Therapy in Patients with Lung Cancer and Hepatitis C
Presenter: Marco Tagliamento- Abstract
Loading... -
+
EP08.01-089 - Efficacy and Safety of Immune Checkpoint Inhibitors in Treating Brain Metastases in Patients With Non-small Cell Lung Cancer
Presenter: Fei Teng- Abstract
Loading... -
+
EP08.01-090 - Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront.
Presenter: Teresa Gorria- Abstract
Loading... -
+
EP08.01-091 - Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront
Presenter: Teresa Gorria- Abstract
Loading... -
+
EP08.01-093 - ICI in Combination With Chemotherapy or Anti-angiogenic Agents as Second-Line Orbeyondtreatment for Advanced Non-small Cell Lung Cancer
Presenter: Lin Wu- Abstract
Loading... -
+
EP08.01-094 - A Phase II Study of Camrelizumab combined with Apatinib and Albumin Paclitaxel in Advanced Non-squamous NSCLC (CAPAP-lung)
Presenter: Lin Wu- Abstract
Loading... -
+
EP08.01-095 - Efficacy and Safety of Combining Endostar with Camrelizumab plus Chemotherapy in Advanced NSCLC Patients: A Multi-Center Retrospective Study
Presenter: Lin Wu- Abstract
Loading... -
+
EP08.01-096 - Lung Immune Prognostic Index is Prognostic in Patients Treated with PD-1 Inhibitor Combined with Chemotherapy for Non-small Cell Lung Cancer
Presenter: Anning Xiong- Abstract
Loading... -
+
EP08.01-097 - Landscape and Dynamic Changes of Peripheral Immune Cells in Non-small Cell Lung Cancer Patients with First-line Immunotherapy
Presenter: Xiangling Chu- Abstract
Loading... -
+
EP08.01-098 - Evaluating Risk Factors for Pneumonitis in Stage III NSCLC Patients Receiving Durvalumab after Definitive Chemoradiation
Presenter: xiaokui Mo- Abstract
Loading... -
+
EP08.01-099 - Activity of aPD1-MSLN-CART Cells against Metastatic Lung Cancer in a Phase 1 Trial
Presenter: Xiaorong Dong- Abstract
Loading... -
+
EP08.01-100 - Unlocking Primary Resistance to Checkpoint Inhibitors in Non-small Cell Lung Cancer by Metagenomic and Metabolomic
Presenter: Xiaorong Dong- Abstract
Loading... -
+
EP08.01-101 - Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLC
Presenter: Yiqing Huang- Abstract
Loading... -
+
EP08.01-102 - Anlotinib Combined with PD-1 Inhibitors May Benefit Advanced Non-small Cell Lung Cancer Patients After Failure of EGFR-TKI Therapy
Presenter: Lian Yu- Abstract
Loading... -
+
EP08.01-103 - Combination of Anlotinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer
Presenter: Lian Yu- Abstract
Loading... -
+
EP08.01-104 - Baseline Tumor Size and Survival Outcomes among Patients with Advanced NSCLC treated with First-Line Immunotherapy
Presenter: Yuji Uehara- Abstract
Loading... -
+
EP08.01-105 - Efficacy of First-Line Immune Checkpoint Inhibitors in Patients with Advanced NSCLC harboring KRAS, MET, FGFR, RET, BRAF, and HER2 Alterations
Presenter: Yuji Uehara- Abstract
Loading... -
+
EP08.01-106 - PD-1/PD-L1 Inhibitors Increase Myocardial Infarction in Osimertinib-Treated Patients with Non-Small Cell Lung Cancer
Presenter: Lucheng Zhu- Abstract
Loading... -
+
EP08.01-107 - The Increase of Blood Intratumor Heterogeneity Is Associated with Unfavorable Outcomes of ICIs Plus Chemotherapy in NSCLC
Presenter: Juan Zhou- Abstract
Loading... -
+
EP08.01-108 - Real-Life Costs and Benefit of First-Line Pembrolizumab for Advanced NSCLC - A Propensity-Score Matched Case-Control Study
Presenter: Vanessa Rambousek- Abstract
Loading... -
+
EP08.01-109 - TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC
Presenter: Martin Forster- Abstract
Loading... -
+
EP08.01-110 - Trial in Progress: A Phase 2 Multicenter Study (IOV-LUN-202) of Autologous Tumor-infiltrating Lymphocyte (TIL) Cell Therapy (LN-145) in mNSCLC
Presenter: Jason Alan Chesney- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-001 - Concurrent Aumolertinib and Cerebral Radiotherapy as First-Line Treatment for EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases
Presenter: Ying Wang- Abstract
Loading... -
+
EP08.02-002 - Aumolertinib in the Treatment of Activated EGFR Mutation Advanced NSCLC Patients with Interstitial Pneumonia
Presenter: Jie Tan- Abstract
Loading... -
+
EP08.02-003 - Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation andctDNA Cleared Analysis
Presenter: YanWei Li- Abstract
Loading... -
+
EP08.02-004 - Aumolertinib in Treatment-Naïve EGFR-mutant NSCLC Patients With Brain Metastases: Primary Efficacy and Safety Data from the ARTISTRY
Presenter: Huijuan Wang- Abstract
Loading... -
+
EP08.02-005 - A Prospective Non-randomized Observational Study on Efficacy and Its Relative Factors of Pemetrexed Combined With EGFR-TKIs in NSCLC
Presenter: Huijuan Wang- Abstract
Loading... -
+
EP08.02-006 - Data from Real World to Evaluate the Efficacy of Almonertinib in EGFR-mutant NSCLC Patients
Presenter: Huijuan Wang- Abstract
Loading... -
+
EP08.02-007 - Disease Burden and Clinical Outcomes of Advanced ROS1 Positive NSCLC with Different Fusion Partners
Presenter: Zihua Zou- Abstract
Loading... -
+
EP08.02-008 - Tumor Invasiveness and Clinical Outcomes between Metastatic ROS-1 and ALK Positive NSCLC
Presenter: Zihua Zou- Abstract
Loading... -
+
EP08.02-009 - Progression Pattern, Resistance Mechanism and Subsequent Therapy for ALK Positive NSCLC in the Era of Second—Generation ALK—TKIs
Presenter: Zihua Zou- Abstract
Loading... -
+
EP08.02-010 - Low-Dose Dacomitinib as First-Line Therapy for Driver-Positive Advanced Non-small Cell Lung Cancer: A Multicenter Real-World Study in China
Presenter: Liang Gong- Abstract
Loading... -
+
EP08.02-011 - Design of a Phase I Trial (TOTEM) to Test Repotrectinib in Combination with Osimertinib in Advanced, Metastatic EGFR-Mutant NSCLC
Presenter: Andrés Aguilar- Abstract
Loading... -
+
EP08.02-012 - Real-world Analysis of the Efficacy and Safety of lorlatinib in Patients with ALK-Positive Non-small Cell Lung Cancer in Korea
Presenter: Beung-chul AHN- Abstract
Loading... -
+
EP08.02-013 - Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC
Presenter: Amanda Gibson- Abstract
Loading... -
+
EP08.02-014 - Impact of East Asian Ancestry on Response to First-Line Osimertinib: A Real-World Canadian Cohort
Presenter: Amanda Gibson- Abstract
Loading... -
+
EP08.02-015 - The Utility of Liquid Biopsies for Management of Stage IV Non-small Cell Lung Cancer (NSCLC) in an Academic Community Medical Center
Presenter: Alisha Paro Maity- Abstract
Loading... -
+
EP08.02-016 - Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs
Presenter: Benjamin Besse- Abstract
Loading... -
+
EP08.02-017 - Time on Treatment for Patients Treated With Anti-EGFR Tyrosine Kinase Therapy for Metastatic NSCLC: Real-World Experience Data
Presenter: Lior Apter- Abstract
Loading... -
+
EP08.02-018 - Phase 1/2 Study of BLU-451, a Small Molecule Inhibitor of EGFR, in EGFR Exon 20 Insertion-Mutant Incurable Advanced Cancers
Presenter: Alexander Spira- Abstract
Loading... -
+
EP08.02-019 - Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Presenter: Alexander Spira- Abstract
Loading... -
+
EP08.02-020 - Preclinical Activity of NVL-655 in a Patient-Derived NSCLC Model with Lorlatinib-Resistant ALK G1202R/T1151M Mutation
Presenter: Anupong Tangpeerachaikul- Abstract
Loading... -
+
EP08.02-021 - A Phase II Trial of Upfront Aumolertinib (HS-10296) plus Radiotherapy for EGFR Mutated Non-small-cell Lung Cancer Patients with Brain Metastases
Presenter: Yi Tang- Abstract
Loading... -
+
EP08.02-022 - Investigating Partners in Crime: Osimertinib Resistance Mechanisms in Non-small Cell Lung Cancer Using Focused CRISPR Screen
Presenter: Bengisu Uluata Dayanc- Abstract
Loading... -
+
EP08.02-023 - Differentiation Syndrome in a Patient with Non-Small-Cell Lung Cancer Harboring IDH2 Mutation Treated with Enasidenib.
Presenter: Bhoomika Sukhadia- Abstract
Loading... -
+
EP08.02-024 - Research Efforts in Systemic Therapy of Lung Cancer With Brain Metastasis From 2015-21: A clinicaltrial.gov Registry Analysis
Presenter: Bindu Krishnappa Venugopal- Abstract
Loading... -
+
EP08.02-025 - Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial
Presenter: Byoung Chul Cho- Abstract
Loading... -
+
EP08.02-026 - Real-world Efficacy of EGFR-TKI in Advanced NSCLC and Clinical Predictors of Outcome in Maharaj Nakorn Chiangmai Hospital in Thailand.
Presenter: Chaiyut Charoentum- Abstract
Loading... -
+
EP08.02-027 - T790M Detection Rate After First-Line Treatment with Bevacizumab Plus 1st or 2nd Generation EGFR-TKI in Advanced NSCLC
Presenter: Chao-Chi Ho- Abstract
Loading... -
+
EP08.02-028 - Germline HRR Mutations in Metastatic NSCLC and Impact on Progression-Free Survival: A Single-Center Retrospective Study
Presenter: Chetan Vakkalagadda- Abstract
Loading... -
+
EP08.02-029 - Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment
Presenter: James Chih-Hsin Yang- Abstract
Loading... -
+
EP08.02-030 - Tusamitamab Ravtansine in Patients with NSQ NSCLC and Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
Presenter: Christine Soufflet- Abstract
Loading... -
+
EP08.02-031 - NRF2 Pathway Signature Predicts KEAP1/NFE2L2 Mutations and Reveals Alternative Pathway-Activating Mutations in NSCLC
Presenter: Christoph Arolt- Abstract
Loading... -
+
EP08.02-032 - High Efficiency Multiplex Detection of Molecular Alterations in Supernatants of Pleural Effusion and Cerebrospinal Fluid
Presenter: Clara Mayo de las Casas- Abstract
Loading... -
+
EP08.02-033 - Anlotinib in Elderly Patients With Advanced Non-squamous NSCLC Who Had Not Received Systemic Chemotherapy: A Single-Arm, Phase II Study
Presenter: da zhao- Abstract
Loading... -
+
EP08.02-034 - OCELOT - Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L
Presenter: Daniel Breadner- Abstract
Loading... -
+
EP08.02-035 - Clinical Utility of Liquid Biopsy After Progression to First and Second-Generation TKIs in Advanced EGFR Mutant NSCLC Patients
Presenter: David Heredia- Abstract
Loading... -
+
EP08.02-036 - Selpercatinib Striking Response in a Case of Cerebral and Auditory Canal Metastasis of RET Fusion-Positive Non-Small-Cell Lung Cancer
Presenter: Diana Moreira Sousa- Abstract
Loading... -
+
EP08.02-037 - Small Cell Transformation in a Patient with RET Fusion Positive Lung Adenocarcinoma on Pralsetinib.
Presenter: Anastasios Dimou- Abstract
Loading... -
+
EP08.02-038 - Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis
Presenter: Shuai Fu- Abstract
Loading... -
+
EP08.02-039 - An Effective Treatment for EGFR-mutated Lung Adenocarcinoma with Symptomatic Leptomeningeal Metastases Using Aumolertinib
Presenter: Xinyong Zhang- Abstract
Loading... -
+
EP08.02-040 - Dacomitinib Induced Febrile Neutropenia: a Rare Serious Adverse Event
Presenter: Debapriya Mondal- Abstract
Loading... -
+
EP08.02-041 - NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study
Presenter: Alexander Drilon- Abstract
Loading... -
+
EP08.02-042 - EGFR-TKI +/- Antiangiogenics for EGFR-mutated Advanced NSCLC
Presenter: Laercio Lopes DaSilva- Abstract
Loading... -
+
EP08.02-043 - The Current State of Biomarker Testing in Lung Cancer as Seen by Health Care Providers
Presenter: Daniel A. Saez- Abstract
Loading... -
+
EP08.02-044 - Adding Alectinib Rescues Progression on Osimertinib Due to Acquired ALK p.R1275Q Variant in EGFR p.L858R-mutated NSCLC
Presenter: Edyta Maria Urbanska- Abstract
Loading... -
+
EP08.02-045 - Phase 1/2 Study of BLU-945 in Patients With Common Activating EGFR-Mutant Non-Small Cell Lung Cancer
Presenter: Elaine Shum- Abstract
Loading... -
+
EP08.02-046 - Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)
Presenter: Elio Gregory Pizzutilo- Abstract
Loading... -
+
EP08.02-047 - The Impact of CGP on the Decision-making Process in ALK+ aNSCLC After Failure of 2nd/3rd-Generation ALK TKIs
Presenter: Elizabeth Dudnik- Abstract
Loading... -
+
EP08.02-048 - Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial
Presenter: Federico Cappuzzo- Abstract
Loading... -
+
EP08.02-049 - A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations
Presenter: Frans Opdam- Abstract
Loading... -
+
EP08.02-050 - A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis
Presenter: shencun Fang- Abstract
Loading... -
+
EP08.02-051 - High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC
Presenter: Yun Fan- Abstract
Loading... -
+
EP08.02-052 - Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients With BRAF V600E- Mutation Positive Metastatic NSCLC
Presenter: Yun Fan- Abstract
Loading... -
+
EP08.02-053 - Non-small Cell Lung Cancer withMETExon14 Skipping Mutation: Literature Review of Real-World Evidence Data
Presenter: Fernanda Estevinho- Abstract
Loading... -
+
EP08.02-054 - Efficacy and Safety of TKI Dose Reduction - Can Less Mean More?
Presenter: Fernando Pereira da Silva- Abstract
Loading... -
+
EP08.02-055 - Targeting Lung Adenocarcinoma Cells with a Novel Disulfide Reductase Inhibitor
Presenter: Fraser Johnson- Abstract
Loading... -
+
EP08.02-056 - Coexisting MET Exon 14 Skipping Mutation and MET Amplification in a Patient with Complete Response to MET Inhibitors
Presenter: Flávia Amaral Duarte- Abstract
Loading... -
+
EP08.02-057 - Mechanism of Resistance to Second-Line Aumolertinib and Therapeutic Regime after Resistance
Presenter: Lingxin Feng- Abstract
Loading... -
+
EP08.02-058 - A Case Series of Patients With Kras KRAS G12C Mutation Treated With Sotorasib - Croatian Experience
Presenter: Fran Seiwerth- Abstract
Loading... -
+
EP08.02-059 - EGFR Tyrosine Kinase Inhibitors and Combination Strategies in First-line Treatment of Advanced NSCLC: A Network Meta-analysis
Presenter: Gilberto de Castro- Abstract
Loading... -
+
EP08.02-060 - How Do Oncologists Treat Patients With EGFR Exon-20 Mutant NSCLC Outside of Clinical Trials? Updated Analysis From the European EXOTIC Registry
Presenter: Giannis Mountzios- Abstract
Loading... -
+
EP08.02-061 - Treatment Sequences in ALK-rearranged Non-small Cell Lung Cancer; What Happens in the Real World?
Presenter: Grace Chazan- Abstract
Loading... -
+
EP08.02-062 - Evaluation of In Silico Tools to Determine Potential Actionability of Missense Variants with Experimental Therapies for NSCLC
Presenter: Lena Chae- Abstract
Loading... -
+
EP08.02-063 - SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC
Presenter: Qing Zhou- Abstract
Loading... -
+
EP08.02-064 - ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)
Presenter: Qing Zhou- Abstract
Loading... -
+
EP08.02-065 - Response to Systemic Anti-Cancer Therapy in Uncommon EGFR Mutations
Presenter: Hazel M O'Sullivan- Abstract
Loading... -
+
EP08.02-066 - Real-World Data on the Side Effects of Alectinib, Brigatinib and Lorlatinib
Presenter: Debra Montague- Abstract
Loading... -
+
EP08.02-067 - Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases
Presenter: Meijuan Huang- Abstract
Loading... -
+
EP08.02-068 - ALK-Dependent Resistance Mechanism to Ensartinib Differs Between the ALK Fusion Subtypes Variant 1 (V1) and Variant 3 (V3)
Presenter: Jie Huang- Abstract
Loading... -
+
EP08.02-069 - A Retrospective Study of Aumolertinib Monotherapy or Combination Therapy Treated EGFR-mutated NSCLC Patients with Leptomeningeal Metastases
Presenter: siyuan Huang- Abstract
Loading... -
+
EP08.02-070 - High Incidence of Peridiagnosis Thromboembolic Events In Patients with BRAF Mutant Lung Cancer
Presenter: Inmaculada Aparicio Salcedo- Abstract
Loading... -
+
EP08.02-071 - Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib +/- Radiation Therapy in a Real-World Canadian Cohort
Presenter: Ishjot Litt- Abstract
Loading... -
+
EP08.02-072 - The Predictive Value of Longitudinal Monitoring of Mutated EGFR in Plasma of Advanced NSCLC Patients on First-Line EGFR-TKIs
Presenter: Joanna Chorostowska-Wynimko- Abstract
Loading... -
+
EP08.02-073 - Clinical and Genomic Analysis of Primary and Secondary MET Fusions with Intact Kinase Domain in Lung Cancer
Presenter: Bo Jin- Abstract
Loading... -
+
EP08.02-074 - Impact of Germline BRCA1/2 Alterations on EGFR Mutant Advanced Non-small Cell Lung Cancer Outcomes
Presenter: Jyoti D. Patel- Abstract
Loading... -
+
EP08.02-075 - Maintained Complete Response for 8+ Years with Erlotinib Alone in Advanced Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion
Presenter: Jens Benn Sørensen- Abstract
Loading... -
+
EP08.02-076 - Efficacy and Safety Evaluations of Anlotinib in Patients with Advanced Non-small Cell Lung Cancer Treated with Bevacizumab
Presenter: Fenge Jiang- Abstract
Loading... -
+
EP08.02-077 - Two Phase III Trials of Aumolertinib Plus Chemotherapy for NSCLC with EGFR and Concomitant non-EGFR Driver Genes /Tumor Suppressor Genes
Presenter: Jie Wang- Abstract
Loading... -
+
EP08.02-078 - Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES)
Presenter: Ying Cheng- Abstract
Loading... -
+
EP08.02-079 - The Use of Lung Adenocarcinoma Patient-Derived Xenografts and Organoids to Study GDP-KRAS G12C Inhibitor Resistance
Presenter: Joshua Rosen- Abstract
Loading... -
+
EP08.02-080 - EGFR Testing Practices, Treatment Choice and Clinical Outcomes in Advanced NSCLC in a Real-World Setting
Presenter: Janakiraman Subramanian- Abstract
Loading... -
+
EP08.02-081 - Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC
Presenter: Joel W. Neal- Abstract
Loading... -
+
EP08.02-082 - Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study
Presenter: Jae Yun Lee- Abstract
Loading... -
+
EP08.02-083 - Real World Treatment and Outcomes in EGFR-mutated Advanced Non-small Cell Lung Cancer Patients: A Nationwide Cohort for 1,932 Thai Patients
Presenter: Kakanan Tienchai- Abstract
Loading... -
+
EP08.02-084 - Evaluation of Tumor Heterogeneity (TH) as a Prognostic Biomarker in Osimertinib treated Non-Small Cell Lung Cancer Patients
Presenter: Karthikeyan Murugesan- Abstract
Loading... -
+
EP08.02-085 - In vitro Activity and Potential Resistance Mutations Against BI-4020, a 4th-generation EGFR-TKI
Presenter: Kenichi Suda- Abstract
Loading... -
+
EP08.02-086 - Randomized Double-blind Placebo-controlled trial of Nicotinamide and EGFR-TKIs for EGFR-mutated Lung Adenocarcinoma
Presenter: Young-Chul Kim- Abstract
Loading... -
+
EP08.02-087 - A 28-Years Old Pregnant Woman Diagnosed as ALK-Rearrangement Lung Adenocarcinoma With Multiple Brain Metastasis - Case Report
Presenter: Simona Laštíkova- Abstract
Loading... -
+
EP08.02-088 - Mutational Status of KRAS, STK11 and CDKN2A Genes as Predictors of Response to Antiangiogenic Agents in Non-small Cell Lung Cancer Patients
Presenter: Laura Gutiérrez Sainz- Abstract
Loading... -
+
EP08.02-089 - Toxicity of Sequential Tyrosine Kinase Inhibitors After Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer
Presenter: Lauren Jones- Abstract
Loading... -
+
EP08.02-090 - Sotorasib Drug-Drug Interactions: Essential Guidance Requested by Physicians Worldwide
Presenter: Leila-Sophie Otten- Abstract
Loading... -
+
EP08.02-091 - Disease Monitoring of EGFR-mutated NSCLC Patients Treated with TKIs via EGFR Status in Circulating ctDNA
Presenter: Yan Li- Abstract
Loading... -
+
EP08.02-092 - Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib
Presenter: Na Li- Abstract
Loading... -
+
EP08.02-093 - Loss of Tumor Endothelial QKI Expression Results in Pronounced Reductions in Metastasis and Remodeling of the Tumor Microenvironment
Presenter: lincy edatt- Abstract
Loading... -
+
EP08.02-094 - Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma (ARISE): A Multicenter, Open-Label, Single-Arm Trial
Presenter: Gen Lin- Abstract
Loading... -
+
EP08.02-095 - Successful Treatment of EGFR Exon 19 Deletion with TP53 and ERBB2 20ins Mutation in Stage IVB NSCLC Patient with Aumolertinib
Presenter: Chunling Liu- Abstract
Loading... -
+
EP08.02-096 - Different Epidermal Growth Factor Receptor Inhibitor Generations Plus Antiangiogenic for EGFR-Mutated NSCLC: A Meta-Analysis
Presenter: Leen Al-Kraimeen- Abstract
Loading... -
+
EP08.02-097 - Prevalence, Clinical Characteristics and Survival of Patients With Brain Metastases and KRAS Mutation Lung Cancer in Argentina
Presenter: Luis Basbus- Abstract
Loading... -
+
EP08.02-098 - Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab±Platinum in First-Line Metastatic NSCLC
Presenter: Martin Reck- Abstract
Loading... -
+
EP08.02-099 - Liquid Biopsies as a Tool for Monitoring Patients with Metastatic ALK-positive NSCLC
Presenter: Maiken Parm Ulhoi- Abstract
Loading... -
+
EP08.02-100 - Combination of Bevacizumab and Continuation of EGFR-TKIs in NSCLC Patients beyond Gradual Progression
Presenter: Ziyi Xu- Abstract
Loading... -
+
EP08.02-101 - Real-world Data from KRAS-mutant Advanced NSCLC: the ATLAS Multicenter Cohort Study
Presenter: Maristella Bungaro- Abstract
Loading... -
+
EP08.02-102 - Feasibility and Clinical Utility of ctDNA for Detection of Sensitizing and Resistance EGFR Mutations in Patients with Non-small Cell Lung Cancer
Presenter: Marta Garcia de Herreros- Abstract
Loading... -
+
EP08.02-103 - Lorlatinib for ALK+ NSCLC Patients Pretreated with Second-Generation ALK Inhibitors: Canadian Real-World Experience
Presenter: Martin Rupp- Abstract
Loading... -
+
EP08.02-104 - Osimertinib in Untreated EGFR-Mutant Non-small Cell Lung Cancers: Overall Survival and Budget Impact Analysis in Real-World
Presenter: Martina Lorenzi- Abstract
Loading... -
+
EP08.02-105 - KRAS p.G12 Mutated Advanced Non-Small Cell Lung Cancer. Characteristics and Outcomes from a Danish Nationwide Observational Study
Presenter: Matilde Tejlbo Frost- Abstract
Loading... -
+
EP08.02-106 - KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations
Presenter: Matthias Scheffler- Abstract
Loading... -
+
EP08.02-107 - Molecular Biomarker Testing and Initiation of Targeted Therapy in Minority Patients with Stage IV Non-small Cell Lung Cancer
Presenter: Matthew Villanueva, PharmD- Abstract
Loading... -
+
EP08.02-108 - Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study
Presenter: Marina Chiara Garassino- Abstract
Loading... -
+
EP08.02-109 - A Drug-Drug Interaction Study of Mobocertinib and Midazolam in Patients With Advanced Non-Small Cell Lung Cancer
Presenter: Michael J. Hanley- Abstract
Loading... -
+
EP08.02-110 - Plasma-based Molecular Profiling to Guide Treatment Decisions in Patients with Advanced NSCLC and Limited Tissue Biopsy
Presenter: Miguel Garcia Pardo- Abstract
Loading... -
+
EP08.02-111 - RMC-4630, a SHP2 Inhibitor, in Combination with Sotorasib for Advanced KRASG12C NSCLC After Failure of Prior Standard Therapies: A Phase 2 Trial
Presenter: Melissa L Johnson- Abstract
Loading... -
+
EP08.02-112 - Precision Treatment of Non-small Cell Lung Cancer Has a Profound Impact on Outcomes in a Canadian Province
Presenter: Michelle Liane Dean- Abstract
Loading... -
+
EP08.02-113 - Clinico-genomic Characteristics of Patients with Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Presenter: Masanobu Okahisa- Abstract
Loading... -
+
EP08.02-114 - Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients
Presenter: Moritz Glaser- Abstract
Loading... -
+
EP08.02-115 - A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan
Presenter: Motohiro Tamiya- Abstract
Loading... -
+
EP08.02-116 - Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors
Presenter: Miguel Villalona Calero- Abstract
Loading... -
+
EP08.02-117 - Online CME Improves Clinicians’ Ability to Identify and Manage Patients with NSCLC and EGFR Exon 20 Insertion Mutations
Presenter: Michelle Arielle Worst- Abstract
Loading... -
+
EP08.02-118 - TRUST-II: A Global Phase II Study for Taletrectinib inROS1fusion Positive Lung Cancer and Other Solid Tumors
Presenter: Misako Nagasaka- Abstract
Loading... -
+
EP08.02-119 - RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer
Presenter: Nicole K Yun- Abstract
Loading... -
+
EP08.02-120 - MET Alterations at Presentation in NSCLC Patients Harboring EGFR Mutations and ALK, RET and ROS1 fusions
Presenter: Núria Jordana- Abstract
Loading... -
+
EP08.02-121 - The Landscape of Anti-neoplastic Drugs for Malignant Pleural Effusion in Non-small Cell Lung Cancer: A Systematic Review of Clinical Trials
Presenter: Obada Ehab Ababneh- Abstract
Loading... -
+
EP08.02-122 - Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)
Presenter: Oliver Illini- Abstract
Loading... -
+
EP08.02-123 - First Line Osimertinib in Lung Cancer Patients with Postoperative Recurrence
Presenter: Atsushi Osoegawa- Abstract
Loading... -
+
EP08.02-124 - Lorlatinib Treatment Related Adverse Events: Single Centre Real-World Experience in ALK and ROS1-driven NSCLC
Presenter: PARVIN BEGUM- Abstract
Loading... -
+
EP08.02-125 - Tumor Suppressor Gene Alterations Identified at Disease Progression Impact Outcomes in Patients with EGFR-mutant Lung Cancer
Presenter: Paul Stockhammer- Abstract
Loading... -
+
EP08.02-126 - The MOMENT Disease Registry of Patients with Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping
Presenter: Petros Christopoulos- Abstract
Loading... -
+
EP08.02-127 - Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study
Presenter: Bin-Chi Liao- Abstract
Loading... -
+
EP08.02-128 - Long Term Efficacy of SNK01 Plus Pembrolizumab for NSCLC: Expanded Observation from a Phase I/II A Randomized Controlled Trial
Presenter: Hyungjun Park- Abstract
Loading... -
+
EP08.02-129 - Closing the Gaps with Blood-Based Next Generation Sequencing
Presenter: Pratik Vijay Shah- Abstract
Loading... -
+
EP08.02-130 - Tegavivint Exhibits Antitumor Activity and Modulates Macrophage Phenotype in the Non-small Cell Lung Cancer Tumor Microenvironment
Presenter: Raghav Chandra- Abstract
Loading... -
+
EP08.02-131 - Alectinib after Crizotinib Failure in Patients with Advanced ALK‑Positive NSCLC: Results from the Spanish Early Access Program
Presenter: Reyes Bernabé-Caro- Abstract
Loading... -
+
EP08.02-132 - Fatal Interstitial lung disease induced by Osimertinib: a case report
Presenter: Ricardo José Cordeiro- Abstract
Loading... -
+
EP08.02-133 - Sequential Afatinib to Osimertinib in EGFR-mutant NSCLC: A Prospective Observational Study, Gio-Tag Japan Interim Report
Presenter: Ryo Morita- Abstract
Loading... -
+
EP08.02-134 - Real-world Efficacy of Dacomitinib in Patients with Previously EGFR-TKI Treated Non-small Cell Lung Cancer
Presenter: Chien-Yeh Chi- Abstract
Loading... -
+
EP08.02-135 - Anti-EGF Antibodies Significantly Improve the Activity of MET and KRAS Inhibitors in Preclinical Models of Non-small Cell Lung Cancer (NSCLC)
Presenter: Silvia Garcia-Roman- Abstract
Loading... -
+
EP08.02-136 - Final Analysis of a Phase II Study: Anlotinib Plus Docetaxel in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer
Presenter: Juan Shen- Abstract
Loading... -
+
EP08.02-137 - Prospective Study of Aumolertinib in NSCLC Patients with EGFR Sensitive Mutations Who Are Intolerant to Osimertinib Treatment
Presenter: Shun Lu- Abstract
Loading... -
+
EP08.02-138 - SAFFRON: Ph3 Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib
Presenter: Shun Lu- Abstract
Loading... -
+
EP08.02-139 - A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs
Presenter: Shun Lu- Abstract
Loading... -
+
EP08.02-140 - MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib
Presenter: Myung-Ju Ahn- Abstract
Loading... -
+
EP08.02-141 - ‘Our’ EGFR population - experience in a secondary center
Presenter: Sofia Campos Silva- Abstract
Loading... -
+
EP08.02-142 - Effects of Afatinib on the Treatment and Prognosis of Brain Metastasis in Advanced EGFR Mutation (+) NSCLC
Presenter: Sung Yong Lee- Abstract
Loading... -
+
EP08.02-143 - Shortening of the Turn around time (TAT) in the Examination of Rapid On-Site cytologic Evaluation (ROSE) at transbronchial biopsy.
Presenter: Yoshihiro Taguchi- Abstract
Loading... -
+
EP08.02-144 - The Impact of CNS Recurrence on Post-recurrence Survival in Patients with EGFR-mutation-positive Non-small-cell Lung Cancer
Presenter: Tatsuro Okamoto- Abstract
Loading... -
+
EP08.02-145 - An Efficacy Analysis of Advanced Non Small Cell Lung Cancer With MET Exon 14 Skipping in the Real World
Presenter: Fei Teng- Abstract
Loading... -
+
EP08.02-146 - Proposal of Foretinib as Second-Line TKI after Capmatinib/Tepotinib Treatment Failure in NSCLC with MET Exon 14 Mutation
Presenter: Toshio Fujino- Abstract
Loading... -
+
EP08.02-147 - Clinical Outcomes in Patients with or without Cell Cycle Gene Alterations in EGFR mutated Non-Small Cell Lung Cancer
Presenter: Turja Chakrabarti- Abstract
Loading... -
+
EP08.02-148 - Extended Follow-up of Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Lung Cancer
Presenter: Victor Moreno- Abstract
Loading... -
+
EP08.02-149 - Spanish Multicenter Retrospective Study of Real-Life Experience of Advanced NSCLC with EGFR Exon 20 Insertions Treated With Amivantamab
Presenter: Víctor Albarrán-Artahona- Abstract
Loading... -
+
EP08.02-150 - Molecular Heterogeneity of Compound Epidermal Growth Factor Receptor (EGFR) Mutations in Lung Adenocarcinoma (LAC)
Presenter: Ramesh Bulusu- Abstract
Loading... -
+
EP08.02-151 - A Real World Evidence of Lorlatinib for Taiwanese with advanced ALK Positive Non-Small Cell Lung Cancer
Presenter: Wade Fang- Abstract
Loading... -
+
EP08.02-152 - Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis
Presenter: Zhaoxia Wang- Abstract
Loading... -
+
EP08.02-153 - The Efficacy and Safety of EGFR-TKIs plus Anlotinib in Maintenance Therapy for Oligoprogressive Advanced or Metastatic EGFR Mutant NSCLC
Presenter: Zhaoxia Wang- Abstract
Loading... -
+
EP08.02-154 - Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial
Presenter: Hualin Chen- Abstract
Loading... -
+
EP08.02-155 - The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients
Presenter: Yen Hsiang Huang- Abstract
Loading... -
+
EP08.02-156 - Real-World Treatment Patterns and Impact of Comorbidity Burden on Treatment Duration for Patients with ALK+ NSCLC in the US
Presenter: Yin Wan- Abstract
Loading... -
+
EP08.02-157 - Acquired EGFR Exon 19 Deletion Is a Resistance Mechanism to BRAF/MRK Inhibition in BRAF V600Emutant NSCLC
Presenter: Fang Wu- Abstract
Loading... -
+
EP08.02-158 - Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-negative NSCLC
Presenter: Lin Wu- Abstract
Loading... -
+
EP08.02-159 - Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study
Presenter: Lin Wu- Abstract
Loading... -
+
EP08.02-160 - A Pooled Efficacy and Safety Analysis of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Immunotherapy
Presenter: Lin Wu- Abstract
Loading... -
+
EP08.02-161 - An Exploratory Study on Biomarkers Related to Primary Resistance Of EGFR-TKIs Therapy in Lung Cancer
Presenter: Lin Wu- Abstract
Loading... -
+
EP08.02-162 - Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series
Presenter: Xiuning Le- Abstract
Loading... -
+
EP08.02-163 - Real-World Case Series on Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer
Presenter: Xiuning Le- Abstract
Loading... -
+
EP08.02-164 - The Effect of Metformin on Survival Outcomes of Advanced EGFR-mutant NSCLC Patients Treated with EGFR TKIs in Thailand
Presenter: Siriwimon Saichaemchan- Abstract
Loading... -
+
EP08.02-166 - Brain Metastases in Patients with ALKrearranged or ROS1-fusion Non-small-Cell Lung Cancers in China
Presenter: Shaoyu Yang- Abstract
Loading... -
+
EP08.02-167 - Diverse Effects of Radiotherapy for Osimertinib Acquired Resistance Non-small Cell Lung Cancer: Gene Matters
Presenter: Yasi Xu- Abstract
Loading... -
+
EP08.02-168 - Efficacy, Safety and Treatment Courses for Patients with ALK Oncogene Positive NSCLC; Retrospective Data in Single Institute
Presenter: Yuki Akazawa- Abstract
Loading... -
+
EP08.02-169 - Research of Aumolertinib Combined with Bevacizumab for Advanced NSCLC Lung Cancer with EGFR Sensitive Mutation
Presenter: Dian Sheng Zhong- Abstract
Loading... -
+
EP08.02-171 - PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion‒Positive Metastatic Non‒Small Cell Lung Cancer (NSCLC)
Presenter: Rosario Garcia- Abstract
Loading... -
+
EP08.02-172 - Effect of EGFR Inhibition on Bone Health in NSCLC Patients without Skeletal Metastasis
Presenter: Marcella Mandruzzato- Abstract
Loading... -
+
EP08.02-173 - Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings
Presenter: Joshua Sabari- Abstract
Loading... -
+
EP08.02-174 - RET Fusions as Primary Oncogenic Drivers and Secondary Acquired Resistance to EGFR TKI in a Large Cohort of Non-Small-Cell Lung Cancers
Presenter: Chunyue Wang- Abstract
Loading...
-
+
EP08.03 - Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease
-
+
EP08.03-001 - A Clinical Study on the Safety and Efficacy of Aumolertinib Combined with SBRT in the EGFR-mutant NSCLC with Brain Parenchymal Oligometastases
Presenter: chunyu He- Abstract
Loading... -
+
EP08.03-002 - Local Ablative Therapy in Oligoprogressive NSCLC - Results from a Tertiary Cancer Center of India
Presenter: Anil Tibdewal- Abstract
Loading... -
+
EP08.03-003 - Surgery for Primary Tumor is Associated with Prolonged Overall Survival in Patients with Oligometastatic NSCLC
Presenter: Jose Francisco Corona-Cruz- Abstract
Loading... -
+
EP08.03-004 - Outcomes of Oligometastatic Non-Small Cell Lung Cancer Patients Undergoing Surgical Resection: A Single Center Experience
Presenter: Fulden Gorguner- Abstract
Loading... -
+
EP08.03-005 - HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours
Presenter: Fiona McDonald- Abstract
Loading... -
+
EP08.03-006 - Survival After Radical Treatment of Oligometastatic Non-small Cell Lung Cancer: A Multicenter Analysis
Presenter: Isabelle Opitz- Abstract
Loading... -
+
EP08.03-007 - Spontaneous Regression in Metastatic Non-small Cell Lung Cancer: A Case Report
Presenter: Maria La Mantia- Abstract
Loading... -
+
EP08.03-008 - Whether Immunotherapy Should Be Maintained or Not After Acquired Resistance in Advanced Nsclc
Presenter: Shun Lu- Abstract
Loading...
first
prev
